ALL

Allstate is firing on every cylinder the MD&A says it watches: FY2025 revenue rose 5.6% to $67.7B while net income more than doubled to $10.3B (+120.3%) and diluted EPS hit $38.06 (+124.0%). The five-year history shows why this matters — net income swung from a -$1.29B loss in 2022 and roughly breakeven in 2023 to $4.67B in 2024 and now $10.3B. That arc is the signature of a property-casualty underwriting cycle turning hard in the carrier's favor: rate increases earned in across the book while the loss/combined ratio that management flags as its key metric improved. The result is a 33.6% ROE and a 15.2% net margin, with stockholders' equity up 42.8% to $30.6B (helped by retained earnings +17.1% to $62.4B and a recovery in the AOCI fixed-income mark referenced in the impairment risk factor). Operating cash flow of $10.1B (+13.2%) comfortably funds the capital return — $1.23B of buybacks (shares -2.1%) and $1.04B of dividends (+7.7%).

The balance sheet is sound for an insurer: 2.91x liabilities/equity is normal for the model, long-term debt fell 7.4% to $7.49B, and the low $678M cash balance is not a red flag because the float is invested in the securities portfolio. Against all of this, the valuation is the thesis. At $221.17 the stock trades at 5.8x EPS and 0.8x sales for a business compounding book value, buying back stock, and earning a 33%+ return on equity. Even insurers structurally trade at low multiples, but this is cheap on its own history and leaves room for a re-rate as the market gains confidence the earnings power is more than a one-year spike.